Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Atherosclerosis leading to cardiovascular disease (CVD) is the main cause of mortality and morbidity in patients with rheumatoid arthritis (RA). Paraoxonase1 (PON1) is the best understood member of plasma paraoxonases with anti-atherogenic properties.
Spanish RA (n = 549) consecutively recruited from 1 single center and 477 ethnically matched healthy controls were included in a case-control study. The concentration of PON1 was evaluated by means of an enzyme-linked immunosorbent sssay (ELISA). An arylesterase/paraoxonase assay kit was used to evaluate PON1 activity. Sample genotyping was performed by using TaqMan assays-on-demand. All results were expressed as medians ± interquartile range. One-way ANOVA comparisons were done using a nonparametric Kruskall-Wallis test. P values under 0.05 were considered to be significant.
The concentration of PON1 in the RA group was higher than in control group (p = 0.0003), although the differences were not significant when PON1 activities were compared between both groups. No significant differences were found related to distributions of rs662 genotypes in RA patients compared to healthy controls. Among rs854860 polymorphisms, overall genotype was widely distributed between RA patients and controls. Overall PON1 concentration in plasma was not significantly different between individuals carrying any of rs662 (p = 0.8501) or rs854860 (p = 0.2741) polymorphisms. Although PON1 levels were not associated with any of the SNPs in the study, differences appear when enzyme activities are compared for each SNP separately. CVD in RA patients correlate with increased PON1 levels and lower PON1 activity.
Although protective role of PON1 against oxidative damage in vivo could be related to other activities, in our study arylesterase activity was useful to identify phenotypic differences with emphasis placed on two SNPs coding for nonconservative amino acid changes in the functional protein.
Goronzy JJ, Weyand CM (2005) Rheumatoid arthritis. Immunol Rev 204:55–73. https://doi.org/10.1111/j.0105-2896.2005.00245.x CrossRef
Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208:228–251. https://doi.org/10.1111/j.0105-2896.2005.00338.x CrossRef
Sharma J, Bhar S, Devi CS (2017) A review on interleukins: the key manipulators in rheumatoid arthritis. Mod Rheumatol 27:723–746. https://doi.org/10.1080/14397595.2016.1266071 CrossRef
Angelotti F, Parma A, Cafaro G et al One year in review 2017: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 35:368–378
Klareskog L, Amara K, Malmström V (2014) Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 26:72–79. https://doi.org/10.1097/BOR.0000000000000016 CrossRef
Le Rossignol S, Ketheesan N, Haleagrahara N (2018) Redox-sensitive transcription factors play a significant role in the development of rheumatoid arthritis. Int Rev Immunol 37:129–143. https://doi.org/10.1080/08830185.2017.1363198 CrossRef
Tsimikas S (2006) Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8:55–61 CrossRef
Schmidt A, Geigenmüller S, Völker W, Buddecke E (2006) The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt -->NF-kappaB signalling pathways in human vascular endothelial cells. Basic Res Cardiol 101:109–116. https://doi.org/10.1007/s00395-005-0582-z CrossRef
Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498–507 CrossRef
Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149–157 CrossRef
Mackness MI, Hallam SD, Peard T, Warner S, Walker CH (1985) The separation of sheep and human serum “A”-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp Biochem Physiol B 82:675–677 CrossRef
Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542–547 CrossRef
van Himbergen TM, van Tits LJH, Roest M, Stalenhoef AFH (2006) The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64:34–38
Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154 CrossRef
Salisbury D, Bronas U (2014) Inflammation and immune system contribution to the etiology of atherosclerosis: mechanisms and methods of assessment. Nurs Res 63:375–385. https://doi.org/10.1097/NNR.0000000000000053 CrossRef
Tajbakhsh A, Rezaee M, Rivandi M, Forouzanfar F, Afzaljavan F, Pasdar A (2017) Paraoxonase 1 (PON1) and stroke; the dilemma of genetic variation. Clin Biochem 50:1298–1305. https://doi.org/10.1016/j.clinbiochem.2017.08.001 CrossRef
Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20:2441–2447 CrossRef
Julià A, Domènech E, Chaparro M, García-Sánchez V, Gomollón F, Panés J, Mañosa M, Barreiro-de Acosta M, Gutiérrez A, Garcia-Planella E, Aguas M, Muñoz F, Esteve M, Mendoza JL, Vera M, Márquez L, Tortosa R, López-Lasanta M, Alonso A, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Gisbert JP, Marsal S (2014) A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. Hum Mol Genet 23:6927–6934. https://doi.org/10.1093/hmg/ddu398 CrossRef
Rodríguez-Carrio J, López-Mejías R, Alperi-López M, López P, Ballina-García FJ, González-Gay MÁ, Suárez A (2016) Paraoxonase 1 activity is modulated by the rs662 polymorphism and IgG anti-high-density lipoprotein antibodies in patients with rheumatoid arthritis: potential implications for cardiovascular disease. Arthritis Rheumatol (Hoboken, NJ) 68:1367–1376. https://doi.org/10.1002/art.39609 CrossRef
Roest M, van Himbergen TM, Barendrecht AB, Peeters PHM, van der Schouw YT, Voorbij HAM (2007) Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Investig 37:187–196. https://doi.org/10.1111/j.1365-2362.2007.01769.x CrossRef
Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451–1457 CrossRef
Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN (1999) Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19:330–335 CrossRef
- Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis
José Ramón Lamas
- Springer London
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II